期刊文献+

Update on the treatment of type 2 diabetes mellitus 被引量:41

Update on the treatment of type 2 diabetes mellitus
下载PDF
导出
摘要 To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus(T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2 DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2 DM, with an emphasis on agents introduced within the last decade. To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.
出处 《World Journal of Diabetes》 SCIE CAS 2016年第17期354-395,共42页 世界糖尿病杂志(英文版)(电子版)
关键词 Type 2 diabetes mellitus TREATMENT Oral ANTIDIABETIC AGENTS INJECTABLE ANTIDIABETIC AGENTS OLDER people Renal IMPAIRMENT Future treatments Type 2 diabetes mellitus Treatment Oral antidiabetic agents Injectable antidiabetic agents Older people Renal impairment Future treatments
  • 相关文献

参考文献1

二级参考文献19

  • 1Chinese Medical Association. Hypoglycemic treatment of type 2 diabetes. Chinese guideline for the diagnosis and treatment of type 2 diabetes (2007 edition). Beijing: Publisher of Beijing University; 2008: 10-11.
  • 2Di Grande A, Vancheri F, Giustolisi V, Giuffrida C, Narbone G, Licata M, et al. Metformin-induced lactic acidosis in a type 2 diabetic patient with acute renal failure. Clin Ter 2008; 159: 87-89.
  • 3Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Cocbrane Database Syst Rev 2006; 25: CD002967.
  • 4Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contra-indications. Eur J Intern Med 2002; 13: 428-431.
  • 5Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
  • 6Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract 2000; 6: 442-446.
  • 7Khan JK, Pallaki M, Tolbert SR, Hornick TR. Lactic acidemia associated with metformin. Ann Pharmacother 2003; 37: 66-69.
  • 8Lu H J, Tang JL, Yuan QY, Jia WP, Xiang KS. The normal range of plasma lactic acid in Chinese. Shanghai Med J (Chin) 2005; 28: 27-29.
  • 9Seidowsky A, Nseir S, Houdret N, Fourrier E Metformin associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009; Epub ahead of print.
  • 10Davis TM, Jackson D, Davis WA, Bruce DG, Chubb R The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol 2001; 52: 137-144.

同被引文献342

引证文献41

二级引证文献212

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部